MedPath

Clinical Pharmacology Study of CS-3150 Drug-drug interaction study between CS-3150 and amlodipine in healthy Japanese subjects

Phase 1
Completed
Conditions
Healthy volunteers
Registration Number
JPRN-jRCT2080223324
Lead Sponsor
DAIICHI SANKYO Co.,Ltd.
Brief Summary

In study 1, the pharmacokinetics of esaxerenone was not affected by amlodipine when esaxerenone 2.5 mg was coadministered with amlodipine 10 mg. In study 2, AUC for amlodipine was increased by approximately 1.2 fold, but Cmax for amlodipine was not increased when amlodipine 2.5 mg was coadministered with esaxerenone 5 mg. It was considered that there were no safety concerns when esaxerenone was administered concomitantly with amlodipine.

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
Male
Target Recruitment
44
Inclusion Criteria

1)Japanese male
2)Persons >= 20 years and =< 45 years of age at the time of informed consent
3)Persons with a body mass index (BMI; calculated by body weight [kg]/height [m]2) of >= 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination

Exclusion Criteria

1)Persons with hypersensitivity or idiosyncratic reactions to a drug, (such as penicillin allergy)
2)Persons with drug or alcohol dependence

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
pharmacokinetics<br>Pharmacokinetics and safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath